Evaluation of the effect of Thiamine in the prevention of post-thrombotic syndrome in patients with deep vein thrombosis of the lower extremities

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221106056416N1

Enrollment

Registered

2022-12-29

Start date

2022-12-06

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post thrombotic syndrome. Postthrombotic syndrome

Interventions

Intervention 1: Intervention group: Receive 300 mg thiamine tablets daily in addition to standard DVT treatment. Intervention 2: Control group: receiving placebo in addition to standard DVT treatment.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: patients Have had a first episode of isolated DVT in the iliofemoral veins within 30 days and have not taken anticoagulant therapy previously Physical status (ASA) class I and II

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The amount of Villalta index score in patients with DVT in the third and sixth months after starting treatment with thiamine 300 mg daily. Timepoint: at The end of the third month and at the end of the sixth month after starting the treatment. Method of measurement: Clinical examination by a specialist based on the Villalta index.	—

Secondary

Measure	Time frame
. Timepoint: . Method of measurement: .	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaziar Bazrafshan

Hamedan University of Medical Sciences

m.bazrafshan@umsha.ac.ir+98 81 3826 9335

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026